The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees.
Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine1.
The German company was always focused on innovation and bringing original products to the market but yesterday, they announced that, the company will establish a new separate business for the development and commercialization of own biosimilars2.
Boehringer Ingelheim started more than 30 years ago as a pioneer in biopharmaceuticals with the development and manufacturing of biopharmaceutical therapeutics. Today, the company’s biopharmaceuticals unit is one of the leading companies in this field straight following its strategy to serve best in class development and manufacturing for its clients and Boehringer Ingelheim itself.
“We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines”, commented Prof. Dr. Wolfram Carius, member of the Board of Managing Directors and responsible for Operations. “We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality Biosimilars understanding patients’ needs.”
It seems Boehringer Ingelheim will not be the last originator company to enter the “attractive” biosimilars area.
2-Boehringer Ingelheim Press Release, 26.09.2011